Search Results
Your search for ,had matches 18483 pages
Showing 11451 - 11500ESMO World GI 2017: Study Explores Association of Mediterranean Diet Components With Advanced Colorectal Polyps
The benefits of a Mediterranean diet are well known when it comes to colorectal protection, but it’s hard to know specifically what elements of the diet are the healthiest. Now a new study, presented by Fliss Isakov et al at the ESMO 19th World Congress on Gastrointestinal Cancer, suggests...
European Commission Expands Use of Ceritinib for First-Line Use in ALK-Positive Advanced NSCLC
On June 29, the European Commission approved expanding the use of ceritinib (Zykadia) to include the first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)–positive. Approval follows a positive opinion granted...
ESMO World GI 2017: Pegilodecakin Plus FOLFOX in Advanced Pancreatic Cancer
Clinical data on an investigational immuno-oncology drug pegilodecakin (PEGylated human interleukin-10, also known as AM0010) was presented by Hecht et al at the ESMO 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain (Abstract O-004). Pegilodecakin is being evaluated in an ongoing...
ESMO World GI 2017: Phase I Data on Anti–PD-1 Antibody BGB-A317 in Hepatocellular Carcinoma
Preliminary results from patients with advanced hepatocellular carcinoma enrolled in a phase I study of the investigational anti–programmed cell death protein 1 (PD-1) antibody BGB-A317 in advanced solid tumors were presented by Yen et al at the ESMO 19th World Congress on Gastrointestinal...
First-Line Cetuximab vs Bevacizumab Plus Chemotherapy in KRAS Wild-Type Advanced Colorectal Cancer
A phase III trial has shown no significant difference in overall survival with first-line cetuximab (Erbitux) vs bevacizumab (Avastin) plus chemotherapy in patients with advanced or metastatic KRAS wild-type colorectal cancer. These study findings were reported by Venook et al in JAMA. The trial...
Study Estimates Risks of Breast and Ovarian Cancers in BRCA1/2-Mutation Carriers
In a prospective cohort study reported in JAMA, Kuchenbaecker et al derived estimates of cumulative risks for breast, ovarian, and contralateral breast cancers among women carrying BRCA1 or BRCA2 mutations. Study Details The study involved data from 6,036 BRCA1 and 3,820 BRCA2 carriers recruited...
Underused Blood Test Could Improve Treatment for Large Swath of Patients With Colon Cancer
A simple blood test could improve treatment for more than one in six patients with stage II colon cancer, suggests new research from the Mayo Clinic. Researchers also discovered that many patients who could benefit from the test likely aren’t receiving it. These findings were published by...
Outcome by Age With Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer
As reported in the Journal of Clinical Oncology by Brose et al, a prespecified analysis of the phase III double-blind SELECT trial of lenvatinib (Lenvima) vs placebo in radioiodine-refractory differentiated thyroid cancer showed progression-free survival benefits in both older and younger...
First-Line Nivolumab vs Chemotherapy in Advanced NSCLC With PD-L1 Expression ≥ 5%
As reported by Carbone et al in The New England Journal of Medicine, the phase III CheckMate 026 trial has shown no progression-free survival benefit for first-line nivolumab (Opdivo) vs platinum-based chemotherapy in patients with recurrent or stage IV non–small cell lung cancer with...
EHA 2017: Ixazomib Plus Lenalidomide/Dexamethasone in Newly Diagnosed Multiple Myeloma With No Stem Cell Transplant, Followed by Maintenance Ixazomib
Data from two phase I/II clinical trials evaluating ixazomib (Ninlaro) in patients with newly diagnosed multiple myeloma was presented at the 2017 European Hematology Association (EHA) Annual Meeting (Abstracts S408, S780). Both studies evaluated ixazomib plus lenalidomide (Revlimid) and...
ICML 2017: Nivolumab Shows Durable Response in Relapsed or Progressed Classical Hodgkin Lymphoma, Regardless of Brentuximab Vedotin History
Extended follow-up data demonstrated responses from nivolumab (Opdivo) in adult patients with relapsed or progressed classical Hodgkin lymphoma after autologous stem-cell transplant (ASCT), irrespective of brentuximab vedotin (Adcetris) therapy history. Results from the phase II CheckMate-205 study ...
EHA 2017: Updated CTL019 ELIANA Data Show Durable Remission Rates in Children, Young Adults With Relapsed/Refractory B-Cell ALL
Updated results from the ELIANA clinical trial demonstrated CTL019 (tisagenlecleucel) remission rates are maintained at 6 months in relapsed/refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL). These data from this pivotal trial of CTL019 show that 83% (52...
EHA 2017: The DYNAMO Study: Duvelisib in Double-Refractory Follicular Lymphoma and Small Lymphocytic Lymphoma
Long-term follow-up data from the DYNAMO study, which met its primary endpoint of overall response rate (ORR; P = .0001) at the final analysis, was presented at the 22nd Congress of the European Hematology Association (EHA) (Abstracts S777, E1130). DYNAMO is a phase II clinical study...
Secondhand Smoke Exposure Among Nonsmoking Cancer Survivors
According to the Centers for Disease Control and Prevention (CDC), tobacco use and exposure accounts for about one-third of all cancer-related deaths in the United States. Moreover, exposure to secondhand tobacco smoke is attributable to more than 7,000 lung cancer–related deaths each year in ...
Early Symptom Reporting Can Extend Life for Patients With Advanced Cancer
In most cases, oncology doctors and nurses only assess their patients’ symptoms during regular checkups. Between visits, patients typically report symptoms only if there is a more severe problem. A study, funded in part by the Conquer Cancer Foundation (CCF) of ASCO, suggests increased...
FDA Grants Regular Approval to Dabrafenib and Trametinib Combination for Metastatic NSCLC With BRAF V600E Mutation
On June 22, 2017, the U.S. Food and Drug Administration granted regular approvals to dabrafenib (Tafinlar) and trametinib (Mekinist) administered in combination for patients with metastatic non–small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. These ...
FDA Approves Daratumumab in Combination With Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved the use of the monoclonal antibody daratumumab (Darzalex) in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide...
Impact of Palliative Care on End-of-Life Services for Patients Dying in a Hospital
In a single-center retrospective analysis reported in the Journal of Oncology Practice, Wiesenthal et al found that among patients dying in a hospital, those with palliative care in place at final admission received less diagnostic testing and other services not associated with promoting patient...
Atezolizumab as First-Line or Subsequent Treatment in PD-L1–Selected Advanced NSCLC
In the phase II BIRCH trial, atezolizumab (Tecentriq) was found to produce higher response rates as first-line or subsequent therapy in patients with advanced non–small cell lung cancer (NSCLC) with higher levels of programmed cell death ligand 1 (PD-L1) expression. Study findings were...
Positive Results for APHINITY, but Value of Benefit of Dual HER2 Blockade Questioned
The results of the long-awaited APHINITY trial are in, and although the phase III study met its primary endpoint, it failed to establish dual HER2 blockade as the optimal adjuvant treatment for early HER2-positive breast cancer. After 3 years of follow-up, the addition of pertuzumab (Perjeta) to...
Pregnancy After Breast Cancer
Findings from a retrospective study showed that women who became pregnant after an early breast cancer diagnosis, including those with estrogen receptor–positive tumors, did not have a higher chance of cancer recurrence and death than those who did not become pregnant.1 Matteo Lambertini, MD, of...
Major Breakthrough in Development of Systemic Targeted Therapy for Midgut Neuroendocrine Tumors
This issue of The ASCO Post discusses a recent trial reported by Strosberg et al in The New England Journal of Medicine that is the first phase III randomized international multicenter clinical trial evaluating lutetium Lu-177 dotatate as a peptide receptor radionuclide therapy in midgut...
Lu-177 Dotatate Improves Progression-Free Survival in Advanced Progressive Midgut Neuroendocrine Tumors
In the phase III NETTER-1 trial reported in The New England Journal of Medicine, Jonathan R. Strosberg, MD, of the Moffitt Cancer Center in Tampa, Florida, and colleagues found that the addition of the targeted radiotherapeutic agent lutetium Lu-177 dotatate to the long-acting repeatable (LAR)...
ASCP/CAP/AMP/ASCO Colorectal Cancer Biomarker Guideline: A Clinician's Perspective
The joint American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and ASCO guideline reported by Sepulveda et al, and reviewed in this issue of The ASCO Post, represents a collaboration of three pathology societies and ASCO ...
Alectinib vs Crizotinib in First-Line Treatment of ALK-Positive NSCLC
In 2011, crizotinib (Xalkori) became the first effective targeted therapy for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC). Now data from a phase III trial show that alectinib (Alecensa), a second-generation ALK inhibitor, outperformed crizotinib, the current...
Identifying Genetic Basis for Extraordinary Clinical Responses May Accelerate Development of New Therapies
Accelerating the discovery of targeted cancer therapies requires defining the targets present in individual tumors, and there are two main ways to do this, David B. Solit, MD, told participants at the inaugural OncoSET Symposium: Emerging Approaches to Precision Medicine in Chicago.1 The...
Newer Approaches With CAR T Cells Explored in CLL
Chimeric antigen receptor (CAR) T-cell therapy is a hot area of research and development in hematologic malignancies and, more recently, some solid tumors. Results have been particularly good in acute lymphocytic leukemia, and one or more CAR T-cell products may be getting close to approval by the ...
Novel Tropomyosin Receptor Kinase Inhibitor Yields High Response Rates Across Tumor Types
Larotrectinib, an oral inhibitor of tropomyosin receptor kinase, showed “striking” activity in adult and pediatric patients with the genetic aberrations known as tropomyosin receptor kinase (TRK) fusion, researchers reported at the 2017 ASCO Annual Meeting.1 Of 55 patients treated with...
Expert Point of View: Richard S. Finn, MD and Ingrid A. Mayer, MD
Richard S. Finn, MD, of the David Geffen School of Medicine at UCLA, Los Angeles, commented on MONARCH 2 and the field of cyclin-dependent kinase 4/6 (CDK4/6) inhibition in general in an interview with The ASCO Post. “MONARCH 2 is confirmatory for the role of CDK4/6 inhibition in estrogen...
Abemaciclib Plus Fulvestrant Delays Breast Cancer Progression in MONARCH 2
In the treatment of metastatic estrogen receptor–positive breast cancer, a highly significant 45% reduction in progression was achieved with abemaciclib, combined with fulvestrant (Faslodex), in the global phase III MONARCH 2 trial, reported at the 2017 ASCO Annual Meeting by George W. Sledge, MD,...
Olaparib Improves Progression-Free Survival in BRCA-Associated Breast Cancer
The PARP INHIBITOR olaparib (Lynparza) improved progression-free survival in women with HER2-negative metastatic breast cancer that was either hormone receptor–positive or triple-negative in patients who had a germline BRCA mutation.1,2 These results of the international, randomized, open-label,...
Two Studies Show Abiraterone Plus Prednisolone/Prednisone Added to Standard Hormone Therapy Improves Survival in Advanced Prostate Cancer
The addition of abiraterone acetate (Zytiga) plus prednisolone/prednisone to standard androgen-deprivation therapy improves survival in men starting treatment for locally advanced or metastatic, hormone--naive prostate cancer, according to the results of two potentially practice-changing studies...
Will the UK’s Departure From the EU Impact Oncology in Europe?
“No man is an island entire of itself; any man’s death diminishes me, because I am involved in mankind. And therefore never send to know for whom the bell tolls; it tolls for thee.” —John Donne (1624) This statement is almost certainly true—and sadly in a negative way not just for the UK but for...
Canadian Cancer Society Report: Nearly 1 in 2 Canadians Expected to Be Diagnosed With Cancer in Their Lifetime
Nearly 1 in 2 Canadians is expected to be diagnosed with cancer in their lifetime, according to a new report—Canadian Cancer Statistics 2017—released by the Canadian Cancer Society (CCS) in partnership with the Public Health Agency of Canada and Statistics Canada. For males, the...
Digital Technology Preferences of Adolescents and Young Adults With Cancer
There is considerable scope to develop digital resources by means of which teenagers and young adults living with cancer can receive information and connect with both professionals and fellow patients. Such tools could help them gain different perspectives on treatment and survivorship, said Esha...
Effect of Postdiagnosis Aspirin and Other NSAIDs on Survival in Colorectal Cancer
As reported by Hua et al in the Journal of Clinical Oncology, long-term survivors of colorectal cancer with KRAS wild-type tumors had improved survival with regular use of any nonsteroidal anti-inflammatory drug (NSAID) post diagnosis. The study involved data from 2,149 patients aged 18 to 74...
Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Adjuvant Therapy for Breast Cancer
The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF (cyclophosphamide, methotrexate, fluorouracil) as adjuvant therapy for breast cancer. The findings were reported in The Lancet Oncology by...
Online Self-Reporting of Symptoms Improves Quality of Life, Extends Survival
When patients with metastatic cancer used a Web-based tool to self-report symptoms proactively during treatment, they lived 5 months longer than did patients assigned to usual care. In addition, they had improved quality of life and fewer emergency room visits and hospitalizations compared with...
Expert Point of View: Cathy Eng, MD, FACP and Alfred Neugut, MD, PhD
Cathy Eng, MD, FACP, the Sophie Caroline Steves Distinguished Professor in Cancer Research at The University of Texas MD Anderson Cancer Center, Houston, said the trial demonstrates “the challenge of analyzing six individually conducted studies in a pooled analysis.” The study’s “potential...
Cancer Gave Me the Impetus to Lose Weight
Fifteen years ago, my internist advised me to lose weight. But after seeing the yo-yo effects of dieting on friends and colleagues, I knew I would find the process of losing weight and gaining it back frustrating, so I ignored my physician’s advice. It wasn’t until I was diagnosed late this past...
USPSTF Emphasizes Importance of Informed Discussions About PSA Screening for Men Aged 55 to 69 Years
For a man aged 55 to 69 years, the decision to be screened for prostate cancer should be an individual one, based on the man’s own values and priorities and discussions with a clinician about the potential benefits and harms of screening, the U.S. Preventive Services Task Force (USPSTF) advised in ...
Adding Vandetanib to Gemcitabine in Locally Advanced or Metastatic Pancreatic Carcinoma
In a UK phase II trial reported in The Lancet Oncology, Middleton et al found that adding the multi–tyrosine kinase inhibitor vandetanib (Caprelsa) to gemcitabine did not improve overall survival in patients with previously untreated locally advanced or metastatic pancreatic carcinoma. John P....
Growing Use of Molecular Pathology May Help Avoid Overtreatment of Early Breast Cancer
The emerging field of molecular pathology focuses on the study and diagnosis of disease through the examination of genes and gene activity within organs and tissues. This information has transformed our thinking about the biologic diversity of breast cancers and has enhanced our treatment...
How Watson for Oncology Is Advancing Personalized Patient Care
After undergoing nearly 5 years of intensive medical training, IBM’s Watson for Oncology cognitive computing system is starting to make good on its promise to accelerate personalized care for patients with cancer. The system has been trained by oncologists at Memorial Sloan Kettering Cancer Center ...
CancerCare Releases Research on Patient Values Initiative
MANY FACTORS can influence treatment decisions patients make concerning their cancer care. These include safety, efficacy, and cost, among other concerns. Recently, CancerCare, a national organization dedicated to providing assistance at no cost to anyone affected by cancer, established the...
Monica Morrow, MD, Tumbled Gender Barriers to Build a Career in Surgical Oncology
Breast cancer surgeon Monica Morrow, MD, came from a town in the far northeast reaches of suburban Philadelphia. “I guess because there were only two girls in our family, I was the son my father never had, and he reared me that way. When we were playing catch, if I missed the ball and got hit in...
Using a Pediatric Treatment Approach to Improve Outcomes for Young Adults With ALL
Three years ago, early results from the U.S. Intergroup C10403 trial,1 which evaluated the effectiveness of treating adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) using an intensive pediatric regimen, showed significant improvement in event-free and overall survival...
Lessons Learned and to Be Learned: Reducing Risk of Subsequent Malignancies in Childhood Cancer Survivors
I recently saw a patient in our survivorship clinic. She was treated at age 15 years for Hodgkin lymphoma and is now in her early 50s. During the prior 2 decades, she had developed both bilateral breast cancer and thyroid cancer, as well as multiple basal cell carcinomas, all occurring within her...
Brief Psychological Interventions Positively Affect Cancer Patients’ Well-Being
Three separate brief psychological interventions aimed at helping cancer patients cope with distress have shown improvements in quality of life and well-being across the continuum of cancer care. The interventions were studied—respectively—in newly diagnosed cancer patients, survivors after cancer...
ICML 2017: 3-Year Follow-up Showed Fourfold Progression-Free Survival Benefit With Ibrutinib vs Temsirolimus at First Relapse in Mantle Cell Lymphoma
Three-year follow-up data from the phase III RAY study in patients with relapsed or refractory mantle cell lymphoma were presented at the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. These results demonstrated that the subset of patients treated with ibrutinib...
